MX350074B - Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina. - Google Patents

Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina.

Info

Publication number
MX350074B
MX350074B MX2013014614A MX2013014614A MX350074B MX 350074 B MX350074 B MX 350074B MX 2013014614 A MX2013014614 A MX 2013014614A MX 2013014614 A MX2013014614 A MX 2013014614A MX 350074 B MX350074 B MX 350074B
Authority
MX
Mexico
Prior art keywords
signal
isv
protein interference
give rise
tendency
Prior art date
Application number
MX2013014614A
Other languages
English (en)
Other versions
MX2013014614A (es
Inventor
Ange Buyse Marie
Baumeister Judith
Paule Lucienne Armanda Bouche Marie
Boutton Carlo
Snoeck Veerle
Staelens Stephanie
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47423024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350074(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2011/067132 external-priority patent/WO2012042026A1/en
Priority claimed from PCT/EP2012/061304 external-priority patent/WO2012175400A1/en
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2013014614A publication Critical patent/MX2013014614A/es
Publication of MX350074B publication Critical patent/MX350074B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

La presente invención se refiere a aspectos específicos pero no limitantes se refiere a: ensayos que se pueden usar para predecir si un ISV dado se someterá a una interferencia de proteínas como se describe en este documento y/o da origen a una señal (no específica) en tal ensayo (tal como por ejemplo en el inmunoensayo ADA). Tales ensayos predictivos se podrían usar por ejemplo para probar si un ISV dado podría tener una tendencia a dar origen a tal interferencia de proteínas y/o tal señal; para seleccionar los ISV´s que no son o son menos propensos a tal interferencia de proteínas o a dar origen a tal señal; como un ensayo o prueba que se puede usar para probar si ciertas modificaciones a un ISV reducirán (total o parcialmente) su tendencia a dar origen a tal interferencia o a tal señal; y/o como un ensayo o prueba que se puede usar para guiar la modificación o mejora de un ISV para reducir su tendencia a dar origen a tal interferencia de proteínas o señal; métodos para modificar y/o mejorar los ISV´s para remover o reducir su tendencia a dar origen a tal interferencia de proteína o a tal señal; modificaciones que se pueden introducir en un ISV que remueven o reducen su tendencia a dar origen a tal interferencia de proteínas o tal señal; los ISV´s que se han seleccionado específicamente (por ejemplo, usando ensayos descritos en este documento) para no tener una tendencia baja (más baja)/reducida para dar origen a tal interferencia de proteínas o a tal señal; los ISV´s modificadas y/o mejoradas que no tienen una tendencia o una tendencia baja(más baja)/reducida.
MX2013014614A 2011-06-23 2012-06-25 Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina. MX350074B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161500360P 2011-06-23 2011-06-23
US201161500464P 2011-06-23 2011-06-23
US201161541368P 2011-09-30 2011-09-30
PCT/EP2011/067132 WO2012042026A1 (en) 2010-09-30 2011-09-30 Biological materials related to c-met
US13/435,567 US8703135B2 (en) 2010-09-30 2012-03-30 Biological materials related to c-Met
PCT/EP2012/061304 WO2012175400A1 (en) 2011-06-23 2012-06-14 Serum albumin binding proteins
PCT/EP2012/062251 WO2012175741A2 (en) 2011-06-23 2012-06-25 Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains

Publications (2)

Publication Number Publication Date
MX2013014614A MX2013014614A (es) 2014-08-01
MX350074B true MX350074B (es) 2017-08-25

Family

ID=47423024

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013014614A MX350074B (es) 2011-06-23 2012-06-25 Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmunoglobulina.
MX2018007826A MX2018007826A (es) 2011-06-23 2013-12-11 Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmonoglobulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018007826A MX2018007826A (es) 2011-06-23 2013-12-11 Tecnicas para predecir, detectar, y reducir la interferencia de proteinas no especificas en ensayos que implican dominios variables individuales de inmonoglobulina.

Country Status (22)

Country Link
US (11) US20180009888A9 (es)
EP (1) EP2723769B2 (es)
JP (6) JP6258199B2 (es)
KR (7) KR102430693B1 (es)
CN (5) CN108663504B (es)
AU (7) AU2012273929B2 (es)
BR (3) BR122018012485B1 (es)
CA (3) CA2837998C (es)
DK (1) DK2723769T4 (es)
ES (1) ES2622006T5 (es)
HU (1) HUE031828T2 (es)
IL (4) IL293163A (es)
IN (1) IN2014CN00373A (es)
LT (1) LT2723769T (es)
MX (2) MX350074B (es)
PH (1) PH12017501178A1 (es)
PL (1) PL2723769T5 (es)
PT (1) PT2723769T (es)
RU (2) RU2700630C2 (es)
SG (4) SG10201805064SA (es)
WO (1) WO2012175741A2 (es)
ZA (1) ZA201309295B (es)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434769B1 (en) 2009-10-30 2020-11-25 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP4218933A1 (en) 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
US20180009888A9 (en) 2011-06-23 2018-01-11 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP3363812A1 (en) 2011-06-23 2018-08-22 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
UY34254A (es) * 2011-08-17 2013-04-05 Glaxo Group Ltd Proteínas y péptidos modificados.
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
WO2013067355A1 (en) 2011-11-04 2013-05-10 Novartis Ag Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
JP2015531350A (ja) * 2012-09-13 2015-11-02 ノバルティス アーゲー 末端修飾を有する抗原結合分子
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11009511B2 (en) * 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
BR122018009619B1 (pt) 2014-05-16 2024-01-02 Ablynx N.V Domínios variáveis de imunoglobulina aperfeiçoados
CN113717280A (zh) * 2014-05-16 2021-11-30 埃博灵克斯股份有限公司 改进的免疫球蛋白可变结构域
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US10526397B2 (en) 2015-01-21 2020-01-07 Inhibrx, Inc. Non-immunogenic single domain antibodies
EA035638B1 (ru) 2015-03-31 2020-07-20 ВиЭйчСКВЕАРД ЛИМИТЕД Полипептиды
CA2981398A1 (en) 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd4 polypeptides with potent anti-hiv activity
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
RS59376B1 (sr) 2015-05-13 2019-11-29 Ablynx Nv Polipeptidi koji regrutuju t-ćelije na bazi tcr-alfa/beta reaktivnosti
EP3294319B1 (en) 2015-05-13 2024-04-24 Ablynx NV T cell recruiting polypeptides based on cd3 reactivity
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US10968271B2 (en) 2015-10-30 2021-04-06 Ablynx N.V. Polypeptides against IL-23
TWI746473B (zh) * 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
NO2768984T3 (es) * 2015-11-12 2018-06-09
US10875918B2 (en) 2015-11-12 2020-12-29 Ablynx N.V. P2X7 receptor binders and polypeptides comprising the same
PL3374392T3 (pl) 2015-11-13 2022-03-28 Ablynx Nv Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
RU2755724C2 (ru) 2015-11-18 2021-09-20 Мерк Шарп И Доум Корп. Pd1/ctla4-связывающие вещества
CR20180279A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de ctla4
JO3744B1 (ar) 2015-11-18 2021-01-31 Merck Sharp & Dohme مواد ربط لـpd1 و/ أو lag3
CN108473564B (zh) * 2015-11-18 2022-04-08 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
KR20180080337A (ko) 2015-11-27 2018-07-11 아블린쓰 엔.브이. Ｃｄ40ｌ을 억제하는 폴리펩티드
HUE051777T2 (hu) 2015-12-04 2021-03-29 Boehringer Ingelheim Int Tumorsejtekben WNT-jelátvitelt antagonizáló biparatópos polipeptidek
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
SG11201811280QA (en) * 2016-06-23 2019-01-30 Ablynx Nv Improved pharmacokinetic assays for immunoglobulin single variable domains
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
CA3041517A1 (en) 2016-10-19 2018-04-26 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
SG10202108972RA (en) * 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
KR20230165374A (ko) * 2017-01-17 2023-12-05 아블린쓰 엔.브이. 개선된 혈청 알부민 결합제
CA3056727A1 (en) 2017-03-31 2018-10-04 Ablynx N.V. Improved immunogenicity assays
KR20200011933A (ko) 2017-05-31 2020-02-04 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드
AR112069A1 (es) 2017-06-02 2019-09-18 Ablynx Nv Inmunoglobulinas que fijan aggrecan
CN111032695A (zh) * 2017-06-02 2020-04-17 默克专利股份有限公司 结合adamts的免疫球蛋白
BR112019025097A2 (pt) 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação a mmp13
TWI826376B (zh) 2017-06-02 2023-12-21 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
KR102625929B1 (ko) 2017-07-19 2024-01-16 브이아이비 브이지더블유 혈청 알부민 결합제
EP3674191B1 (en) 2017-08-23 2021-07-14 Honda Motor Co., Ltd. Air bag device for saddle-type vehicles
KR20200091400A (ko) 2017-10-31 2020-07-30 브이아이비 브이지더블유 신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도
CA3085784A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer driver and controller
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TW202016151A (zh) 2018-06-09 2020-05-01 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
WO2020014194A1 (en) * 2018-07-10 2020-01-16 Regeneron Pharmaceuticals, Inc. Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay
FR3088640A1 (fr) 2018-10-14 2020-05-22 Smart Diagnostix Pharma Nouveau polypeptide se liant specifiquement a la proteine p16
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
JP2022538083A (ja) 2019-06-21 2022-08-31 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
KR20220066035A (ko) 2019-06-21 2022-05-23 소리소 파마슈티컬스 인크. 폴리펩타이드
TW202128756A (zh) 2019-10-02 2021-08-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
CA3158991A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
MX2022006880A (es) 2019-12-06 2022-07-11 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.
KR20220111313A (ko) 2019-12-06 2022-08-09 아블린쓰 엔.브이. TNFα 및 OX40L을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
IL293548A (en) 2019-12-09 2022-08-01 Ablynx Nv Polypeptides comprising immunoglobulin with single variable domains targeting 13 il and tsl
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
WO2021123360A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
KR20230012464A (ko) 2020-02-25 2023-01-26 브이아이비 브이지더블유 류신-풍부 반복 키나제 2 알로스테릭 조절제
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
KR20230074527A (ko) 2020-09-25 2023-05-30 아블린쓰 엔.브이. Il-13 및 ox40l을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
CA3201219A1 (en) 2020-12-04 2022-06-09 Mir Ali Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
EP4259663A1 (en) 2020-12-14 2023-10-18 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
TW202239763A (zh) 2020-12-18 2022-10-16 比利時商艾伯霖克斯公司 包含靶向ＩＬ－６和ＴＮＦ－α的免疫球蛋白單可變結構域的多肽
EP4263610A1 (en) 2020-12-18 2023-10-25 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
TW202241947A (zh) 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
US20240101647A1 (en) 2021-02-05 2024-03-28 Vib Vzw Sarbecovirus binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
IL305318A (en) 2021-02-19 2023-10-01 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
CN113173978B (zh) * 2021-04-22 2024-03-01 温州医科大学 一种对hpv16e6蛋白具有结合亲和力的多肽及其应用
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
TW202330596A (zh) * 2021-11-29 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 經修飾的蛋白或多肽
WO2023110190A1 (en) 2021-12-13 2023-06-22 Heraeus Medical Gmbh Tests and methods for detecting bacterial infection
WO2023111266A1 (en) 2021-12-17 2023-06-22 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
TW202342521A (zh) 2022-02-23 2023-11-01 日商武田藥品工業股份有限公司 條件性雙特異性結合蛋白
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2023240156A1 (en) 2022-06-08 2023-12-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
WO2023242247A1 (en) 2022-06-14 2023-12-21 Ablynx Nv Immunoglobulin single variable domains targeting t cell receptor
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545106C3 (de) 1963-07-16 1979-05-31 Union Carbide Corp., New York, N.Y. (V.St.A.) Verfahren zur Herstellung von linearen Polyarylenpolyäthern
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
ATE153695T1 (de) 1990-11-26 1997-06-15 Akzo Nobel Nv Verfahren zur herstellung von antikörpern
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2001002853A2 (en) 1999-07-05 2001-01-11 K.U. Leuven Research & Development DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
WO2002026829A1 (en) 2000-09-25 2002-04-04 Rega Stichting Vzw Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
AU2003285578B2 (en) 2002-12-03 2010-07-15 Ucb Pharma S.A. Assay for identifying antibody producing cells
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
AU2004204262B2 (en) 2003-01-10 2010-11-04 Ablynx N.V. Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
AU2004205631A1 (en) * 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2005041648A1 (ja) 2003-11-04 2005-05-12 Japan Science And Technology Agency 高脂血症・高アルブミン血症モデル動物
ZA200701656B (en) 2004-08-05 2008-09-25 Genentech Inc Humanized anti-cment antagonists
KR20070086896A (ko) 2004-12-02 2007-08-27 도만티스 리미티드 항­ｉｌ­1ｒ1 단일 도메인 항체 및 치료적 용도
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
CA2962819C (en) 2005-05-18 2021-07-27 Ablynx Nv Improved nanobodies against human serum albumin
NZ563392A (en) 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
WO2006129843A2 (en) * 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
EP1957537A2 (en) 2005-12-01 2008-08-20 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
EA200801170A1 (ru) 2005-12-01 2008-12-30 Домантис Лимитед Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
AU2007209201A1 (en) † 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
AU2007348941B2 (en) * 2006-08-03 2011-08-04 Medimmune Limited Antibodies directed to alphaVbeta6 and uses thereof
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CA2663042A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
ATE536369T1 (de) 2006-10-11 2011-12-15 Ablynx Nv Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung
AU2007328900A1 (en) * 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
JP5484063B2 (ja) 2006-12-08 2014-05-07 レキシコン ファーマシューティカルズ インコーポレーテッド Ａｎｇｐｔｌ３に対するモノクローナル抗体
CA2672595A1 (en) * 2006-12-15 2008-06-19 Guy Hermans Amino acid sequences that modulate the interaction between cells of the immune system
EP2097451A2 (en) * 2006-12-22 2009-09-09 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
AU2008219216A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
AR062123A1 (es) * 2007-07-27 2008-10-15 Inst Nac De Tecnologia Agropec Dominio vhh monomerico derivado de anticuerpos de camelidos anti-vp6 dominio dimerico, metodo de inmunodeteccion de rotavirus, composiciones, metodos de prevencion y tratamiento de infecciones con rotavirus
WO2009032949A2 (en) * 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2201040A1 (en) * 2007-09-24 2010-06-30 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
CA2709399C (en) * 2007-12-28 2021-01-19 Genentech, Inc. Anti-hedgehog antibodies
BRPI0907648B1 (pt) 2008-01-29 2022-01-11 Institute Of Molecular Biology And Genetics National Academy Of Science Of Ukraine Anticorpo isolado humanizado, usos de um anticorpo, métodos para preparar um anticorpo, para gerar anticorpos imunorreativos com slc34a2 e para triar ou identificar agentes ou compostos que modulam slc34a2, composições, ácido nucleico isolado, e, microorganismo hospedeiro
US8217140B2 (en) 2008-04-17 2012-07-10 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
AU2009248049B2 (en) * 2008-05-16 2015-07-23 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
US7858729B2 (en) 2008-05-29 2010-12-28 Novomer, Inc. Methods of controlling molecular weight distribution of polymers and compositions thereof
PL2285408T3 (pl) 2008-06-05 2019-05-31 Ablynx Nv Sekwencje aminokwasowe skierowane przeciwko białkom otoczki wirusa i polipeptydy je zawierające do leczenia chorób wirusowych
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
US8372808B2 (en) 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
EP2403873A1 (en) † 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2411054A2 (en) 2009-03-27 2012-02-01 Glaxo Group Limited Drug fusions and conjugates
WO2010115998A2 (en) * 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
US9150640B2 (en) * 2009-07-10 2015-10-06 Ablynx N.V. Method for the production of variable domains
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
EP2507262A1 (en) * 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
SG181707A1 (en) * 2009-12-18 2012-07-30 Sanofi Sa Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
US8796425B2 (en) 2009-12-23 2014-08-05 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
PE20130527A1 (es) * 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
CN107739407B (zh) 2010-03-10 2021-07-06 根马布股份公司 抗c-MEt的单克隆抗体
EP2552962B1 (en) * 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
WO2011135026A1 (en) 2010-04-30 2011-11-03 Ablynx Nv Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23
SG185354A1 (en) * 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
WO2012042026A1 (en) * 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN103443126B (zh) * 2011-01-06 2016-11-23 葛兰素集团有限公司 结合TGFβ受体II的配体
JP6130350B2 (ja) 2011-03-30 2017-05-17 アブリンクス エン．ヴェー． ＴＮＦαに対する単一ドメイン抗体で免疫障害を処置する方法
WO2012130314A1 (en) † 2011-03-31 2012-10-04 Elara Pharmaceuticals Gmbh Composition comprising docetaxel
EP4218933A1 (en) 2011-06-23 2023-08-02 Ablynx NV Serum albumin binding proteins
US20180009888A9 (en) 2011-06-23 2018-01-11 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
US20150344568A1 (en) 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA2842099A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited Antigen binding constructs
UY34254A (es) 2011-08-17 2013-04-05 Glaxo Group Ltd Proteínas y péptidos modificados.
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
US8614548B2 (en) 2012-01-19 2013-12-24 Sonoco Development Incorporated Electroluminescent display and method for production
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
MX2014014206A (es) 2012-05-22 2015-06-04 Owens Corning Intellectual Cap Producto de espuma laminada y metodos para preparar productos de espuma laminada.
WO2014111550A1 (en) † 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
CN113717280A (zh) * 2014-05-16 2021-11-30 埃博灵克斯股份有限公司 改进的免疫球蛋白可变结构域
AU2015334984A1 (en) 2014-10-21 2017-04-13 Ablynx Nv Treatment of IL-6R related diseases
NO2768984T3 (es) * 2015-11-12 2018-06-09
RU2755724C2 (ru) 2015-11-18 2021-09-20 Мерк Шарп И Доум Корп. Pd1/ctla4-связывающие вещества
JO3744B1 (ar) 2015-11-18 2021-01-31 Merck Sharp & Dohme مواد ربط لـpd1 و/ أو lag3
CR20180279A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de ctla4
CN108473564B (zh) * 2015-11-18 2022-04-08 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
WO2017129630A1 (en) 2016-01-26 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-vwf d'd3 single-domain antibodies and polypeptides comprising thereof
WO2018104444A1 (en) * 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
SG10202108972RA (en) * 2017-01-17 2021-09-29 Ablynx Nv Improved serum albumin binders
CN111032695A (zh) * 2017-06-02 2020-04-17 默克专利股份有限公司 结合adamts的免疫球蛋白
AR120698A1 (es) * 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp

Also Published As

Publication number Publication date
US20180009888A9 (en) 2018-01-11
CA2837998A1 (en) 2012-12-27
BR122017005075B1 (pt) 2022-09-20
BR112013032145B1 (pt) 2022-09-20
JP6982400B2 (ja) 2021-12-17
JP2021107426A (ja) 2021-07-29
IL229503A0 (en) 2014-01-30
BR112013032145A8 (pt) 2018-07-03
HUE031828T2 (en) 2017-08-28
BR112013032145A2 (pt) 2017-12-05
KR102025035B1 (ko) 2019-11-04
SG10201605048XA (en) 2016-07-28
KR20180086280A (ko) 2018-07-30
US20210388062A1 (en) 2021-12-16
IL293163A (en) 2022-07-01
IL250396B (en) 2022-06-01
AU2024200309A1 (en) 2024-02-08
US20180355031A1 (en) 2018-12-13
EP2723769B2 (en) 2022-06-15
JP2024050769A (ja) 2024-04-10
JP2022031790A (ja) 2022-02-22
AU2017204339A1 (en) 2017-07-13
DK2723769T3 (en) 2017-04-03
IL250396A0 (en) 2017-03-30
DK2723769T4 (da) 2022-09-05
CA2837998C (en) 2022-03-01
AU2020230299B2 (en) 2022-10-06
EP2723769A2 (en) 2014-04-30
CA3141978A1 (en) 2012-12-27
BR122018012485B1 (pt) 2022-09-20
RU2019128430A (ru) 2019-10-25
CA3142288A1 (en) 2012-12-27
CN104203975B (zh) 2018-05-11
CN108659121A (zh) 2018-10-16
KR20240033183A (ko) 2024-03-12
CN108663504A (zh) 2018-10-16
MX2018007826A (es) 2021-12-08
KR20210047369A (ko) 2021-04-29
WO2012175741A2 (en) 2012-12-27
KR102240318B1 (ko) 2021-04-15
CN108663504B (zh) 2021-06-22
MX2013014614A (es) 2014-08-01
AU2017204339B2 (en) 2019-03-28
AU2021201506B2 (en) 2023-10-19
PH12017501178A1 (en) 2018-07-23
JP2014520134A (ja) 2014-08-21
US20220119497A1 (en) 2022-04-21
KR102246924B1 (ko) 2021-04-30
KR20190107200A (ko) 2019-09-18
NZ617995A (en) 2016-06-24
PL2723769T5 (pl) 2022-10-17
AU2012273929B2 (en) 2017-04-27
AU2020230299A1 (en) 2020-10-01
CN104203975A (zh) 2014-12-10
EP2723769B1 (en) 2017-01-11
KR20190041513A (ko) 2019-04-22
US20200216532A1 (en) 2020-07-09
IL229503B (en) 2022-06-01
KR20220114104A (ko) 2022-08-17
US20220298227A9 (en) 2022-09-22
US20200325221A1 (en) 2020-10-15
SG10201805064SA (en) 2018-07-30
AU2019201606A1 (en) 2019-04-04
SG10201707604SA (en) 2017-11-29
ES2622006T5 (es) 2022-10-13
LT2723769T (lt) 2017-04-10
SG194982A1 (en) 2013-12-30
KR20140040779A (ko) 2014-04-03
US20210403536A1 (en) 2021-12-30
JP6258199B2 (ja) 2018-01-10
AU2019201606B2 (en) 2021-04-01
ZA201309295B (en) 2015-01-28
US20140199295A1 (en) 2014-07-17
US10858418B2 (en) 2020-12-08
NZ716279A (en) 2017-07-28
AU2021201506A1 (en) 2021-03-25
PT2723769T (pt) 2017-04-04
BR122017005075A2 (pt) 2019-09-03
WO2012175741A3 (en) 2013-02-14
CN108653728B (zh) 2022-11-18
CN108659120A (zh) 2018-10-16
JP2017160230A (ja) 2017-09-14
US11192937B2 (en) 2021-12-07
US20170275360A1 (en) 2017-09-28
RU2700630C2 (ru) 2019-09-18
KR101965462B1 (ko) 2019-04-04
IL293155A (en) 2022-07-01
CN108653728A (zh) 2018-10-16
PL2723769T3 (pl) 2017-07-31
JP6869923B2 (ja) 2021-05-12
US20170275361A1 (en) 2017-09-28
KR102430693B1 (ko) 2022-08-08
US20210388061A1 (en) 2021-12-16
AU2018202782B2 (en) 2020-07-16
JP2018162305A (ja) 2018-10-18
US11192938B2 (en) 2021-12-07
ES2622006T3 (es) 2017-07-05
US20230242620A1 (en) 2023-08-03
RU2014102007A (ru) 2015-11-27
AU2018202782A1 (en) 2018-05-10
IN2014CN00373A (es) 2015-04-03

Similar Documents

Publication Publication Date Title
PH12017501178A1 (en) Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
NZ602056A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2844033C (en) Method for detecting pancreatic cancer
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
BR112016004437A2 (pt) métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
NZ600828A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX341517B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
BR112012008665A2 (pt) tratamento de câncer
BR112012030788B8 (pt) Anticorpo monoclonal, linhagem celular de hibridoma, e métodos para identificar a presença e para determinação quantitativa de uma enzima aad-12
WO2007133822A8 (en) Gitr antibodies for the treatment of cancer
BR112013027867A2 (pt) "método de detectar o nível de um anticorpo anti-ip10 em amostra, anticorpo monoclonal isolado ou porção de ligação de antígeno do mesmo, linhagem de célula de hibridoma e kit"
MX2015012823A (es) Ensayo de combinacion de antigeno-anticuerpo del virus de la hepatitis c (vhc) y metodos y composiciones para usarlo.
ATE504002T1 (de) Erkennung und vorhersage von frühgeburten
RU2012148244A (ru) Способ диагностики онкологических заболеваний и иммуноферментный набор для его осуществления
HK1126274A1 (en) T cell assays t
WO2013106778A3 (en) Non-equilibrium two-site assays for linear, ultrasensitive analyte detection
EP2565647A4 (en) REAGENT FOR TESTING ANTI-TREPONEMA PALLIDUM ANTIBODY
GB201119585D0 (en) Assay
WO2013165969A3 (en) Methods and kits for diagnosing heparin-induced thrombocytopenia
NZ601643A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013119279A3 (en) Assays and methods for the diagnosis of ovarian cancer
BR112013006146B8 (pt) Anticorpos monoclonais, linhagens de célula de hibridoma e métodos para identificar a presença e para a determinação quantitativa de uma enzima aad-1 que confere resistência ao ácido 2,4-diclorofenoxiacético
IN2014MN01760A (es)
EP2588496A4 (en) REAGENTS AND METHODS FOR DIAGNOSIS OF SUFFERING HYDROXYLATED HIF 1

Legal Events

Date Code Title Description
FG Grant or registration